— Know what they know.
Not Investment Advice

REC.MI

Recordati Industria Chimica e Farmaceutica S.p.A.
1W: +3.2% 1M: -4.1% 3M: -12.7% YTD: -3.6% 1Y: -20.6% 3Y: +21.0% 5Y: +21.4%
€50.45 ($58.34)
+4.17 (+9.01%)
 
MIL · Healthcare · Drug Manufacturers - General · €9.5B · Alpha Radar Strong Sell · Power 32
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap€9.5B ($10.9B)
52W Range43.76-55.35
Volume229,589
Avg Volume338,819
Beta0.60
Dividend€1.30
Analyst Ratings
No analyst coverage
Company Info
CEORobert Koremans
Employees4,580
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date1995-03-28
1, Via Matteo Civitali
Milan, MI 20148
IT
39 02 487871
About Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms